# TAXUS Libertē Post Approval Study

> **NCT00997503** · — · COMPLETED · sponsor: **Boston Scientific Corporation** · enrollment: 4199 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** TAXUS Liberté Paclitaxel-Eluting Coronary Stent
- **DRUG:** prasugrel
- **DRUG:** placebo
- **DRUG:** aspirin

## Key facts

- **NCT ID:** NCT00997503
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2013-03
- **Final completion:** 2015-07
- **Target enrollment:** 4199 (ACTUAL)
- **Last updated:** 2015-08-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00997503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00997503, "TAXUS Libertē Post Approval Study". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00997503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*